Cargando…

Efficacy of Oral Medications or Intrauterine Device-Delivered Progestin in Patients with Endometrial Hyperplasia with or without Atypia: A Network Meta-Analysis

The aim of this systematic review was to evaluate the efficacy of oral medication or intrauterine device-delivered progestins in patients with endometrial hyperplasia (EH) with or without atypia. We systematically examined PubMed, EMBASE, the Cochrane Library, and clinicaltrials.gov to identify stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yu-Fei, Fan, Yu, Mu, Yi, Li, Jin-Ke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143726/ https://www.ncbi.nlm.nih.gov/pubmed/37109316 http://dx.doi.org/10.3390/jcm12082980

Ejemplares similares

Comparison of the effectiveness of the levonorgestrel-intrauterine device and oral progestogens on regression of endometrial hyperplasia without atypia
por: Shen, Ye, et al.
Publicado: (2022)

Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management
por: Nwanodi, Oroma
Publicado: (2017)

Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience
por: Wang, Yang, et al.
Publicado: (2019)

A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women
por: Dinnekere Ravi, Ramya, et al.
Publicado: (2021)

Dienogest versus norethisterone acetate in management of endometrial hyperplasia without atypia
por: Girbash, Ehab F., et al.
Publicado: (2023)

Patient experiences of conservative treatment for early stage endometrial cancer and endometrial hyperplasia with atypia using levonorgestrel intrauterine device: A qualitative study
por: O'Hara, Montana, et al.
Publicado: (2021)

The value of MRI in management of endometrial hyperplasia with atypia
por: Natarajan, Purushothaman, et al.
Publicado: (2020)

MicroRNAs as Predictors of Future Uterine Malignancy in Endometrial Hyperplasia without Atypia
por: Lin, Chiao-Yun, et al.
Publicado: (2022)

Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma
por: Lv, Mu, et al.
Publicado: (2022)

Pulsatile tinnitus related to progestin from intrauterine device()
por: Onishi, Ektor Tsuneo, et al.
Publicado: (2015)

Prostatic Stromal Hyperplasia with Atypia
por: Hutchinson, Ryan C., et al.
Publicado: (2013)

Non-atypical endometrial hyperplasia: risk factors for occult endometrial atypia and malignancy in patients managed with hysterectomy
por: Hui, Lee Shi, et al.
Publicado: (2021)

Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis
por: Shao, Fengping, et al.
Publicado: (2023)

Comparison of levonorgestrel-releasing intrauterine device with oral progestins in heavy menstrual bleeding (HMB) cases with uterine leiomyoma (LNG-IUD and oral progestin usage in myoma uteri)
por: Tosun, Ayse Kavasoglu, et al.
Publicado: (2014)

Identification of Genes and Pathways Differentially Expressed in Progestin Responsive Endometrial Cancer and Hyperplasia
por: Gertz, Jay, et al.
Publicado: (2021)

The effect of progestin therapy in advanced and recurrent endometrial cancer: A systematic review and meta‐analysis
por: van Weelden, Willem Jan, et al.
Publicado: (2022)

Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: Is it effective?
por: Baek, Ji Sun, et al.
Publicado: (2016)

Weight Loss During Intrauterine Progestin Treatment for Obesity-associated Atypical Hyperplasia and Early-Stage Cancer of The Endometrium
por: Barr, Chloe E., et al.
Publicado: (2021)

Isolated pulmonary embolism in a patient with progestin intrauterine device and factor V Leiden
por: Jean, Soluny
Publicado: (2019)

Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial*
por: Ørbo, A, et al.
Publicado: (2014)

Dilatation and curettage is more accurate than endometrial aspiration biopsy in early-stage endometrial cancer patients treated with high dose oral progestin and levonorgestrel intrauterine system
por: Kim, Da Hee, et al.
Publicado: (2017)

Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients
por: Mitsuhashi, Akira, et al.
Publicado: (2019)

Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel‐impregnated intrauterine system or oral progestogens
por: Ørbo, A, et al.
Publicado: (2015)

Intrauterine device use and risk of endometrial cancer.
por: Parazzini, F., et al.
Publicado: (1994)

HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
por: Ørbo, Anne, et al.
Publicado: (2016)

HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
por: Ørbo, Anne, et al.
Publicado: (2016)

Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study
por: Kim, Mi Kyoung, et al.
Publicado: (2020)

Intrauterine device survival in Iranian women: systematic review and meta-analysis
por: Farajzadegan, Ziba, et al.
Publicado: (2015)

Prominent decidualization following progestin treatment for endometrial hyperplasia and carcinoma as a mimic of large residual tumor: A cautionary tale
por: Hu, Yang, et al.
Publicado: (2021)

Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment
por: Zhou, Shuang, et al.
Publicado: (2021)

Efficacy of Intrauterine Device in the Treatment of Intrauterine Adhesions
por: Salma, Umme, et al.
Publicado: (2014)

Identification of potential models for predicting progestin insensitivity in patients with endometrial atypical hyperplasia and endometrioid endometrial cancer based on ATAC-Seq and RNA-Seq integrated analysis
por: Hu, Jia-Li, et al.
Publicado: (2022)

Clinical Evaluation of Li Brush Endometrial Samplers for Diagnosing Endometrial Lesions in Women With Intrauterine Devices
por: Han, Lu, et al.
Publicado: (2020)

Response to comment on: Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study
Publicado: (2020)

Relapse of neuromyelitis optica associated with oral progestin
por: Li, Li-Min, et al.
Publicado: (2018)

Hysteroscopic Removal of Intrauterine Device in Pregnancy: A Scoping Review to Guide Personalized Care
por: Stabile, Guglielmo, et al.
Publicado: (2022)

Chlorpromazine Sensitizes Progestin-Resistant Endometrial Cancer Cells to MPA by Upregulating PRB
por: Cui, Yunxia, et al.
Publicado: (2021)

Differential Effects of the Hormonal and Copper Intrauterine Device on the Endometrial Transcriptome
por: Smith-McCune, Karen, et al.
Publicado: (2020)

Letter to editor in response to: Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study
Publicado: (2020)

Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia
por: Behnamfar, Fariba, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8609vvkghimhsf37gm03134lc5